InvestorWire NewsRoom


ANEW MEDICAL, INC. (LEAS) Featured in Coverage of Investor Summit Group’s Q4 Event
November 9, 2022

ANEW MEDICAL, INC. (LEAS) Featured in Coverage of Investor Summit Group’s Q4 Event

ANEW MEDICAL (OTC: LEAS) is poised to disrupt the biopharma industry in a way that hasn’t been seen in decades. Cell and gene therapies are the next wave of therapeutic innovation in the life sciences industry and the practice of medicine. ANEW is dedicated to realizing the potential of gene therapies to offer transformative patient outcomes in areas of high unmet medical need and extending the reach of gene therapies to highly prevalent neurodegenerative disorders like Alzheimer’s and Parkinson’s disease, and amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s disease”). ANEW has assembled a portfolio of gene therapies in partnership with leading scientific institutions, and they have built a core team with extensive experience in the gene therapy, drug development, and the commercialization process. As part of their ongoing business strategy, the company continues to explore potential opportunities to acquire or license new product candidates, as well as opportunities for partnership or collaboration on their existing products in development. The vision is to build one of the world’s leading cell and gene therapy company focused on the prevention and treatment of Alzheimer’s Disease (“AD”) and other neurodegenerative diseases by progressing their current α-Klotho-based AD and ALS programs. The company is an early-stage venture, with research and preclinical programs leading to first-in-man clinical trials of the “anti-aging” α-Klotho gene plasmids delivered inside cells by various means to include lipid nano-particles, electroporation, AAV, and Lentivirus. ANEW is also developing the recombinant secreted Klotho protein (s-KL) and mRNA for injections or infusions to slow cellular and/or systemic aging pathologies to include neurodegenerative diseases, cardiovascular diseases, chronic kidney diseases, fibrosis, bone and muscle wasting, and cancer. The inventors and technical expertise in the company’s academic labs in the U.S. and Spain will help us to achieve these goals and objectives. The company’s management team has done this before – created value in raw technology with great potential, and then conclude deals with corporate partners to buy the company or to license its key assets. Because of the very broad reach in therapeutic activities of the human α-Klotho protein – neurodegeneration, cancer, cardiovascular disease, fibrosis, bone and muscle, chronic kidney disease – e.g. age-related pathologies in general, there are a staggering number of potential clinical applications that can be developed and out-licensed, while other applications can be retained and commercialized by the company. The successful development of a single cell and/or gene therapy product for this broad array of applications is the objective. For more information, visit the company’s website at

To view IBN’s virtual coverage of Investor Summit Group’s Q4 Event, visit

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the companies participating at this quarter’s Investor Summit. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorBrandNetwork (IBN)
Los Angeles, California
310.299.1717 Office
[email protected]

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).